6533b861fe1ef96bd12c4ed9
RESEARCH PRODUCT
Lymphokine activated killer cells.
Albrecht LindemannFriedhelm HerrmannWolfgang OsterRoland Mertelsmannsubject
Cytotoxicity ImmunologicLymphokine-activated killer cellTumor-infiltrating lymphocytesmedicine.medical_treatmentLymphokineHematologyGeneral MedicineImmunotherapyBiologyNatural killer T cellMajor histocompatibility complexLymphocyte ActivationTumor antigenKiller Cells NaturalImmunologymedicinebiology.proteinCytotoxic T cellAnimalsHumansInterleukin-2Killer Cells Lymphokine-Activateddescription
Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma and were associated with considerable toxicity. In view of restricted efficacy and increasing doubts as to whether LAK cells indeed account for the in vivo observed responses, more recent strategies focus on tumor antigen specific cytotoxic T cells or tumor infiltrating lymphocytes. Successful translation of this approach into clinical practice, however, may be dependend on some basic problems of tumor immunology to be solved which were thought to be by-passed by the LAK cell approach.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1989-10-01 | Blut |